University of Cantabria - IDIVAL, Santander, Spain
Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain.
BMJ Open. 2019 Nov 21;9(11):e031904. doi: 10.1136/bmjopen-2019-031904.
Since 2016, the multicase-control study in Spain (MCC-Spain) has focused towards the identification of factors associated with cancer prognosis. Inception cohorts of patients with colorectal, breast and prostate cancers were assembled using the incident cases originally recruited.
2140 new cases of colorectal cancer, 1732 of breast cancer and 1112 of prostate cancer were initially recruited in 12 Spanish provinces; all cancers were incident and pathologically confirmed. Follow-up was obtained for 2097 (98%), 1685 (97%) and 1055 (94.9%) patients, respectively.
Information gathered at recruitment included sociodemographic factors, medical history, lifestyle and environmental exposures. Biological samples were obtained, and 80% of patients were genotyped using a commercial exome array. The follow-up was performed by (1) reviewing medical records; (2) interviewing the patients by phone on quality of life; and (3) verifying vital status and cause of death in the Spanish National Death Index. Ninety-seven per cent of recruited patients were successfully followed up in 2017 or 2018; patient-years of follow-up were 30 914. Most colorectal cancers (52%) were at clinical stage II or lower at recruitment; 819 patients died in the follow-up and the 5-year survival was better for women (74.4%) than men (70.0%). 71% of breast cancers were diagnosed at stages I or II; 206 women with breast cancer died in the follow-up and the 5-year survival was 90.7%. 49% of prostate cancers were diagnosed at stage II and 32% at stage III; 119 patients with prostate cancer died in the follow-up and the 5-year survival was 93.7%.
MCC-Spain has built three prospective cohorts on highly frequent cancers across Spain, allowing to investigate socioeconomic, clinical, lifestyle, environmental and genetic variables as putative prognosis factors determining survival of patients of the three cancers and the inter-relationship of these factors.
自 2016 年以来,西班牙的多病例对照研究(MCC-Spain)一直致力于确定与癌症预后相关的因素。最初招募的病例中,共纳入了来自 12 个西班牙省份的结直肠癌、乳腺癌和前列腺癌的新发病例。所有癌症均为初发且经病理证实。分别对 2140 例结直肠癌、1732 例乳腺癌和 1112 例前列腺癌患者进行了随访,随访率分别为 98%、97%和 94.9%。
在招募时收集的信息包括社会人口统计学因素、病史、生活方式和环境暴露。获得了生物样本,80%的患者使用商业外显子组芯片进行了基因分型。通过以下方式进行随访:(1)查阅病历;(2)通过电话对生活质量进行患者访谈;(3)在西班牙国家死亡索引中核实患者的存活状态和死因。2017 年或 2018 年,97%的入组患者成功随访;患者随访年数为 30914。大多数结直肠癌(52%)在入组时处于临床分期 II 期或更低;随访期间 819 例患者死亡,女性(74.4%)的 5 年生存率优于男性(70.0%)。71%的乳腺癌诊断为 I 期或 II 期;206 例乳腺癌患者在随访期间死亡,5 年生存率为 90.7%。49%的前列腺癌诊断为 II 期,32%诊断为 III 期;随访期间 119 例前列腺癌患者死亡,5 年生存率为 93.7%。
MCC-Spain 在西班牙各地建立了三个针对高发癌症的前瞻性队列,以研究社会经济、临床、生活方式、环境和遗传因素作为潜在的预后因素,以确定三种癌症患者的生存情况及其之间的相互关系。